Analysis of Clinical Efficacy and Influencing Factors of Nerve Growth Factor (NGF) Treatment for Sudden Sensorineural Hearing Loss.
Analysis of Clinical Efficacy and Influencing Factors of Nerve Growth Factor (NGF) Treatment for Sudden Sensorineural Hearing Loss.
复制标题
DOI：
10.1177/01455613231181711
复制
发表时间：
2023-06
期刊：
影响因子：
--
通讯作者：
Zhengrong Liang;Minqian Gao;H. Jia;Wenjing Han;Yiqing Zheng;Yunfeng Zhao;Haidi Yang
中科院分区：
文献类型：
--
作者：
Zhengrong Liang;Minqian Gao;H. Jia;Wenjing Han;Yiqing Zheng;Yunfeng Zhao;Haidi Yang
目的：探讨神经生长因子(NGF)治疗突发性感音神经性聋(SSHL)的临床疗效及影响预后的因素。材料和方法：对中山大学中山大学附属中山大学纪念医院2019年1月至2020年7月收治的101例中重度SSHL患者的临床资料进行回顾性分析。治疗前，对所有患者进行纯音测听(PTA)、听性脑干反应、耳声发射、颞骨计算机断层扫描或内耳磁共振成像检查。57例患者接受常规全身治疗作为对照组，44例患者在常规全身治疗的基础上加用NGF治疗，为试验组。比较两组患者治疗前、治疗后1周、2周、1个月的PTA结果。此外，分析了年龄、性别、患侧、高血压等因素对患者预后的影响。结果：两组患者治疗后PTA均有显著改善，差异有统计学意义(P<；0.05)。对照组听力恢复有效率为42.1%，试验组听力恢复有效率为70.5%，两组比较差异有统计学意义(P<；0.05)。大多数患者在治疗1周后听力有显著改善，有些患者在治疗2周后仍有进步。多因素分析显示高血压和发病天数与治疗结果相关。结论：对于初次治疗后疗效不满意或无明显改善的SSHL患者，二次治疗仍具有临床意义。高血压的存在和延迟治疗是影响治疗效果的负面因素。
Objective: This study aims to examine the clinical efficacy and prognostic factors associated with nerve growth factor (NGF) treatment for sudden sensorineural hearing loss (SSHL). Materials and methods: A retrospective analysis was conducted on the clinical data of 101 patients with moderate or more severe SSHL who underwent secondary treatment at Sun Yat-sen Memorial Hospital of Sun Yat-sen University between January 2019 and July 2020. Prior to treatment, all patients were assessed using Pure Tone Audiometry (PTA), auditory brainstem response, otoacoustic emission, temporal bone computed tomography, or inner ear magnetic resonance imaging. Fifty-seven patients received conventional systemic treatment and served as the control group, while 44 patients received NGF in conjunction with conventional systemic treatment, forming the experimental group. PTA results were compared between the two groups before treatment and at 1 week, 2 weeks, and 1 month post-treatment. Additionally, the impact of age, sex, affected side, hypertension, and other factors on patient prognosis was analyzed. Results: Both groups demonstrated significant PTA improvements following treatment, with a statistically significant difference (P < .05). The hearing recovery effective rate in the control group was 42.1%, while that of the experimental group reached 70.5%, with a statistically significant difference between the groups (P < .05). Most patients experienced notable hearing improvements 1 week after treatment, with some patients still showing progress 2 weeks post-treatment. Multifactor analysis revealed that hypertension and onset days were associated with treatment outcomes. Conclusion: Secondary treatment remains clinically significant for patients with SSHL who have not achieved a satisfactory response or show no clear improvement following initial treatment. The presence of hypertension and delayed treatment are negative factors related to treatment efficacy.